AZD6140

Expert Opinion on Investigational Drugs

Volumn 16, Issue 2, 2007, Pages 225-229

  Tantry, Udaya S ^a   Bliden, Kevin P ^a   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

AZD6140; Coronary artery diseases; P2Y12 receptor blocker; Platelets; Thienopyridines

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; AR C 126532XX; CLOPIDOGREL; EPTIFIBATIDE; ORBOFIBAN; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

ADENOSINE; ANIMALS; CORONARY DISEASE; DRUGS, INVESTIGATIONAL; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2;

EID: 33846817108     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.2.225     Document Type: Article

References (24)

1. YUSUF S, ZHAO F, MEHTA SR et al.; CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS TRIAL INVESTIGATORS: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345:494-502.
2. STEINHUBL SR, BERGER PB, MANN JT III et al.; CREDO INVESTIGATORS: CLOPIDOGREL FOR THE REDUCTION OF EVENTS DURING OBSERVATION. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288:2411-2420.
3. MEHTA SR, YUSUF S, PETERS RJ et al.: Clopidogrel in Unstable Angina to Prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527-533.
4. BERTRAND ME, RUPPRECHT HJ, URBAN P, GERSHLICK AH; CLASSICS INVESTIGATORS: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative study (CLASSICS). Circulation (2000) 102:624-629.
5. GURBEL PA, BLIDEN KP, HIATT BL, O'CONNOR CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107:2908-2913.
6. GURBEL PA, BLIDEN KP, HAYES KM, YOHO JA, HERZOG WR, TANTRY US: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol (2005) 45:1392-1396.
7. MATETZKY S, SHENKMAN B, GUETTA V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109:3171-3175.
8. GURBEL PA, BLIDEN KP, SAMARA W et al.: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol. (2005) 46:1827-1832.
9. AJZENBERG N, AUBRY P, HUISSE MG et al.: Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J. Am. Coll. Cardiol. (2005) 45:1753-1756.
10. BARRAGAN P, BOUVIER JL, ROQUEBERT PO et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv. (2003) 59:295-302.
11. GURBEL PA, BLIDEN KP, GUYER K et al.: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J. Am. Coll. Cardiol. (2005) 46:1820-1826.
12. BLIDEN KP, TANTRY U, ZAMAN K et al.: High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting. J. Am. Coll. Cardiol. (2005) 45:33A.
13. CUISSET T, FRERE C, QUILICI J et al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. (2006) 4:542-549.
14. GURBEL PA, TANTRY US: Drug insight: clopidogrel nonresponsiveness. Nat. Clin. Pract. Cardiovasc. Med. (2006) 3:387-395.
15. TANTRY US, BLIDEN KP, GURBEL PA: Resistance to antiplatelet drugs: current status and future research. Expert Opin. Pharmacother. (2005) 6(12):2027-2045.
16. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. (2006) 27:1038-1047.
17. 12 antagonists. Semin. Tbromb. Hemost. (2005) 31:195-204.
18. PETERS G, ROBBIE G: Single dose pharmacokinetics and pharmacodynamics of AZD6140. Haematologica (2004) 89(Suppl. 7):14-15.
19. PETERS GR, BUTLER KA, WINTER HR, MITCHELL PD: Multiple-doe pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZD6140. World Congress of Cardiology, Barcelona, Spain (2006):P4556.
20. CANNON CP, MAHAFFEY K, HARRINGTON RA et al.: Clinical outcomes with AZD6140, an oral reversible ADP receptor antagonist, compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). J Am. Coll. Cardiol. (2006) 47:199A.
21. GURBEL PA, BLIDEN KP, ZAMAN KA, YOHO JA, HAYES KM, TANTRY US: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation (2005) 111:1153-1159.
22. EMANUELSSON H, MAHAFFEY K, HARRINGTON RA: Can greater inhibition of platelet aggregation be tolerated? evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). J. Am. Coll. Cardiol. (2006) 47:212A.
23. HUSTED S, STOREY RF, HARRINGTON FA et al.: The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). J. Am. Coll. Cardiol. (2006) 47:200A.
24. STOREY RF, HUSTED S, HARRINGTON RA et al.: AZD64 10 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronory syndromes without previous clopidogrel treatment. J. Am. Coll. Cardiol. (2006) 47:204A.